-
CD22-Directed Car T-Cell Therapy Induces Complete Remissions in CD19-Directed Car–Refractory Large B-Cell Lymphoma
Baird et al, Blood 2019
-
Clinical Lessons Learned From the First Leg of the CAR T-Cell Journey
Majzner et al, Nature Medicine 2019
-
Tumor Antigen Escape from CAR T-cell Therapy
Majzner et al, Cancer Discovery 2018
-
CD22-Targeted Car T-Cells Induce Remission in B-All That Is Naive or Resistant to CD19-Targeted Car Immunotherapy
Fry et al, Nature Medicine 2018
Publications
CARGO is advancing a pipeline
of next-generation adoptive
CAR T-cell therapies for cancer
